Kamada (KMDA) to Release Earnings on Wednesday

Kamada (NASDAQ:KMDA) will likely be posting its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $145.0670 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 8:00 AM ET.

Kamada Stock Performance

Kamada stock opened at $8.70 on Monday. Kamada has a 52 week low of $5.54 and a 52 week high of $9.35. The firm has a market capitalization of $500.34 million, a PE ratio of 24.17, a PEG ratio of 0.74 and a beta of 0.94. The business’s 50-day simple moving average is $8.08 and its 200-day simple moving average is $7.34.

Wall Street Analysts Forecast Growth

Several research analysts have commented on KMDA shares. HC Wainwright lifted their price target on Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. Benchmark reiterated a “buy” rating on shares of Kamada in a research note on Thursday, January 8th. Finally, Wall Street Zen upgraded shares of Kamada from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Kamada presently has an average rating of “Moderate Buy” and an average price target of $14.00.

Institutional Trading of Kamada

Several institutional investors have recently bought and sold shares of KMDA. Aristides Capital LLC raised its stake in Kamada by 4.5% during the fourth quarter. Aristides Capital LLC now owns 33,015 shares of the biotechnology company’s stock worth $233,000 after acquiring an additional 1,430 shares in the last quarter. NewEdge Advisors LLC grew its holdings in shares of Kamada by 4.2% in the 3rd quarter. NewEdge Advisors LLC now owns 52,668 shares of the biotechnology company’s stock worth $366,000 after purchasing an additional 2,125 shares during the last quarter. Barclays PLC increased its position in shares of Kamada by 417.1% during the 4th quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 3,862 shares in the last quarter. Two Sigma Investments LP lifted its holdings in Kamada by 4.3% during the 3rd quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock valued at $761,000 after purchasing an additional 4,504 shares during the last quarter. Finally, Man Group plc lifted its holdings in Kamada by 19.9% during the 4th quarter. Man Group plc now owns 34,294 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 5,684 shares during the last quarter. Institutional investors and hedge funds own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.